The news is a drumbeat of clinical wins and market expansion, but the stock's acting like it's got a hangover. 📉 RSI is stuck in the "meh" 40s, and price keeps getting slapped down by the 21-period WMA. Feels like the market yawned at the good news and sold the rallies. Classic "sell the fact" vibes. Until it breaks that heavy resistance, this is a SELL. Let it find a real floor first. #PatiencePays

Whoa, talk about a wild ride! The news is *huge* – tripling their market? That's the kind of catalyst we dream of. But look at the chart: after that insane pump to $3.86, it's come crashing back down. The RSI cooled from "overheated" to "meh," and volume is settling. This screams "buy the rumor, sell the news." The hype might be over for now. I'm saying SELL this pop and wait for a calmer entry. 📉 #PumpAndSigh

The news flow is fantastic – CMS codes tripling their market! But the stock's acting like it got a bad Botox injection. 📉 Oversold RSI and price diving below key averages screams "panic sell." This is a disconnect. I'm buying the fear. #UglyDuckling

STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. Its products include XTRAC and Pharos excimer lasers, VTRAC lamp systems, and TheraClear treatment systems that are used for the treatment of psoriasis, vitiligo, acne, and other skin conditions. The company distributes its products internationally through distributors, and domestically directly to physicians. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.

STRATA Skin Sciences, Inc. SSKN: 0.15 USD

Bullish views

Bearish views